Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FPR1 | P21462 | 2/20 | 0.51 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451482 | 0.91 | ULK1 (0.56) | NPC1RAB9A | |
| SCHEMBL18395563 | 0.90 | KMT2A (0.58) | NPC1RAB9AKMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4714884 | 0.89 | KMT2A (0.56) | NPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL18094875 | 0.87 | ROCK2 (0.47) | KMT2AJAK3 | |
| SCHEMBL23390119 | 0.84 | ULK1 (0.49) | KMT2AFPR2JAK3 | |
| SCHEMBL6037575 | 0.84 | ALDH1A1 (0.52) | KMT2A | |
| SCHEMBL6037572 | 0.84 | ULK1 (0.49) | KMT2AJAK3 | |
| SCHEMBL23390541 | 0.84 | FPR3 (0.53) | RAB9AKMT2AFPR1FPR2 | |
| SCHEMBL2146675 | 0.84 | KMT2A (0.56) | NPC1RAB9AKMT2A | |
| SCHEMBL2146682 | 0.84 | KMT2A (0.56) | NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-04 | — | — | US | disclosed |
| WO-2011035143-A2 | METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252792-A1 | METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION | RHOA, RHOC, ROCK1 | NPC1 1600/4885RAB9A 534/4885KMT2A 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.